drugset / Trial / NCT00038883

Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies

NCT00038883

Non-randomizedSingle-groupOpen-labelTreatment

Summary

High dose chemotherapy followed by transplantation of allogeneic hematopoietic stem cell with the use of Campath-1h, a monoclonal antibody that have a synergistic effect to chemotherapy with minimal toxicity. In addition Campath-1H can improve engraftment of donor cells through its immunosuppressive properties.

Timeline

Start
2001-04-09
Primary completion
2006-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Alemtuzumab Monoclonal antibody 10 mg Intravenous